

## CLAIMS

1. Use of sulfated glycosaminoglycans having an anticoagulant activity of 100 BP units/mg or less for the manufacture of a pharmaceutical preparation for prophylactic priming or curative treatment of the cervix and the myometrium for establishing effective labor in women.
2. Use of a glycosaminoglycan according to claim 1, which belongs to the group consisting of heparan sulfates and depolymerised heparan sulfates.
3. Use of a glycosaminoglycan according to claim 1, which belongs to the group consisting of chondroitin sulfates and depolymerised chondroitin sulfates.
4. Use of a glycosaminoglycan according to claim 1, which belongs to the group consisting of dermatan sulfates or depolymerised dermatan sulfates.
5. Use of a glycosaminoglycan according to claim 1, which belongs to the group consisting of depolymerised heparins having an average molecular weight below 10 000 Da, preferably not higher than 6000 Da.
6. Use of a glycosaminoglycan according to any of claims 1-5, having an anticoagulant activity of 30 BP units/mg or less.
7. Use of a glycosaminoglycan according to claim 2 or 6, having a sulfate/hexosamine ratio below 1.0 and an anticoagulant activity of 10 BP units/mg or less.
8. Use of a glycosaminoglycan according to any of claims 1-7 in combination with oxytocin.

9. Use of glycosaminoglycans according to any of claims 1-7 for the manufacture of a topical pharmaceutical preparation.

10. Use of glycosaminoglycans according to any of claims 1-7 for the manufacture of a parenteral pharmaceutical preparation.